Equity Overview
Price & Market Data
Price: $16.70
Daily Change: +$1.44 / 8.62%
Daily Range: $14.67 - $17.34
Market Cap: $409,235,072
Daily Volume: 432,158
Performance Metrics
1 Week: 7.77%
1 Month: -3.23%
3 Months: -11.43%
6 Months: -16.38%
1 Year: 333.5%
YTD: 14.56%
Company Details
Employees: 31
Sector: Health technology
Industry: Pharmaceuticals: major
Country:
Details
Eton Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing treatments for rare diseases. Its commercial rare disease products include Increlex for the treatment of severe primary igf-1 deficiency; Alkindi Sprinkle for adrenal insufficiency; Galzin for Wilson disease; PKU Golike for phenylketonuria; Carglumic Acid for N-acetylglutamate synthase deficiency; Betaine Anhydrous for homocystinuria; and Nitisinone for tyrosinemia type 1. The company is also developing various product candidates, which are in late-stage development, including ET-400 for treating adrenal insufficiency; ET-600 for diabetes insipidus; Amglidia for neonatal diabetes mellitus; ET-700 for Wilson disease; ET-800 for adrenal insufficiency; and ZENEO hydrocortisone autoinjector for adrenal crisis. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.